BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday,Wall Street Zen reports.

A number of other brokerages have also recently issued reports on BCRX. Wedbush cut their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $13.00 to $11.00 in a research report on Thursday, September 10th. Finally, Weiss Ratings downgraded shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $19.44.

BioCryst Pharmaceuticals Trading Up 3.0%

Shares of BCRX opened at $7.88 on Friday. The stock has a market cap of $2.01 billion, a PE ratio of -5.25 and a beta of 0.55. BioCryst Pharmaceuticals has a 1 year low of $6.23 and a 1 year high of $11.22. The stock has a 50 day simple moving average of $8.75 and a 200-day simple moving average of $8.71.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The business had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. During the same quarter in the previous year, the firm earned $0.15 EPS. BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% on a year-over-year basis. On average, sell-side analysts forecast that BioCryst Pharmaceuticals will post -2.28 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Nykredit A S bought a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at $27,000. IFP Advisors Inc grew its holdings in shares of BioCryst Pharmaceuticals by 2,515.3% during the second quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 3,119 shares during the last quarter. Allworth Financial LP bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth $52,000. Pallas Capital Advisors LLC bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth $101,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of BioCryst Pharmaceuticals in the second quarter valued at $103,000. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.